Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 2/20 | 1.00 |
| ▸ | SHBG | P04278 | 2/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.70 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.70 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.70 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.70 |
| ▸ | AR | P10275 | 1/20 | 0.69 |
| ▸ | ESR1 | P03372 | 2/20 | 0.66 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.66 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nandrolone SCHEMBL28638525 | 1.00 | ALDH1A1 (1.00) | ALDH1A1SERPINA6SHBGSLC22A1THRB | |
| Nandrolone SCHEMBL28993612 | 1.00 | ALDH1A1 (1.00) | ALDH1A1SERPINA6SHBGSLC22A1THRB | |
| Nandrolone SCHEMBL11872554 | 1.00 | ALDH1A1 (1.00) | ALDH1A1SERPINA6SHBGSLC22A1THRB | |
| Nandrolone SCHEMBL11977556 | 1.00 | ALDH1A1 (1.00) | ALDH1A1SERPINA6SHBGSLC22A1THRB | |
| Nandrolone SCHEMBL5021656 | 1.00 | ALDH1A1 (1.00) | ALDH1A1SERPINA6SHBGSLC22A1THRB | |
| Nandrolone SCHEMBL17831191 | 1.00 | ALDH1A1 (1.00) | ALDH1A1SERPINA6SHBGSLC22A1THRB | |
| Nandrolone SCHEMBL11736454 | 1.00 | ALDH1A1 (1.00) | ALDH1A1SERPINA6SHBGSLC22A1THRB | |
| Nandrolone SCHEMBL5017882 | 1.00 | ALDH1A1 (1.00) | ALDH1A1SERPINA6SHBGSLC22A1THRB | |
| Nandrolone SCHEMBL12101449 | 1.00 | ALDH1A1 (1.00) | ALDH1A1SERPINA6SHBGSLC22A1THRB | |
| Nandrolone SCHEMBL22739132 | 1.00 | ALDH1A1 (1.00) | ALDH1A1SERPINA6SHBGSLC22A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202413-B2 | Neuroactive enantiomeric 15-, 16- and 17-substituted steroids as modulators for GABA type-A receptors | WASHINGTON UNIVERSITY (US) | 2019-02-12 | — | — | US | disclosed |
| US-20160251391-A9 | NEUROACTIVE ENANTIOMERIC 15-, 16- AND 17-SUBSTITUTED STEROIDS AS MODULATORS FOR GABA TYPE-A RECEPTORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-01 | — | — | US | disclosed |
| EP-2956466-A1 | NEUROACTIVE ENANTIOMERIC 15-, 16- AND 17-SUBSTITUTED STEROIDS AS MODULATORS FOR GABA TYPE-A RECEPTORS | Washington University (US) | 2015-12-23 | — | — | EP | disclosed |
| US-20150361125-A1 | NEUROACTIVE ENANTIOMERIC 15-, 16- AND 17-SUBSTITUTED STEROIDS AS MODULATORS FOR GABA TYPE-A RECEPTORS | UNIV WASHINGTON (US) | 2015-12-17 | — | — | US | disclosed |
| WO-2014127201-A1 | NEUROACTIVE ENANTIOMERIC 15-, 16- AND 17-SUBSTITUTED STEROIDS AS MODULATORS FOR GABA TYPE-A RECEPTORS | WASHINGTON UNIVERSITY (US) | 2014-08-21 | — | — | WO | disclosed |
| US-20030069217-A1 | Methods of prevention and treatment of ischemic damage | SIMPKINS JAMES W (US) | 2003-04-10 | — | — | US | disclosed |
| WO-2001010430-A9 | USE OF ESTROGEN COMPOUNDS FOR PREVENTION AND TREATMENT OF ISCHEMIC DAMAGE | UNIV FLORIDA (US) | 2002-07-11 | — | — | WO | disclosed |
| US-6350739-B1 | ADMINISTERING ENT-17-BETA-ESTRADIOL TO TREAT STROKE, TRAUMA, HEMORRHAGE, BRAIN DISORDERS AND MYOCARDIUM INFARCTION AND AFTER SURGERY | UNIVERSITY OF FLORIDA RESARCH FOUNDATION, INC. | 2002-02-26 | — | — | US | disclosed |
| EP-1143947-A2 | USE OF ESTROGEN COMPOUNDS FOR PREVENTION AND TREATMENT OF ISCHEMIC DAMAGE | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2001010430-A2 | USE OF ESTROGEN COMPOUNDS FOR PREVENTION AND TREATMENT OF ISCHEMIC DAMAGE | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361125-A1 | NEUROACTIVE ENANTIOMERIC 15-, 16- AND 17-SUBSTITUTED STEROIDS AS MODULATORS FOR GABA TYPE-A RECEPTORS | GABRA4, GABRA5, GABRA3 | ALDH1A1 554/4885SERPINA6 654/4885SHBG 190/4885 |
| US-10202413-B2 | Neuroactive enantiomeric 15-, 16- and 17-substituted steroids as modulators for GABA type-A receptors | GABRA4, GABRA5, GABRA3 | ALDH1A1 554/4885SERPINA6 654/4885SHBG 190/4885 |
| US-20030069217-A1 | Methods of prevention and treatment of ischemic damage | ESRRB, SHBG, ESR2 | ALDH1A1 448/4885SERPINA6 449/4885SHBG 2/4885 |
| US-20160251391-A9 | NEUROACTIVE ENANTIOMERIC 15-, 16- AND 17-SUBSTITUTED STEROIDS AS MODULATORS FOR GABA TYPE-A RECEPTORS | GABRA4, GABRA5, GABRA3 | ALDH1A1 554/4885SERPINA6 654/4885SHBG 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.